Director Kaplan Matthew L. made one open market purchase of Nuvectis Pharma, Inc. ($NVCT) shares in the last year, totaling $64,240, with the most recent on November 5, 2025. This ranks 2,757th among nearly 5,000 insiders by purchase value, well below the average of $1.5 million over 3.3 transactions. No open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 5, 2025 | Nuvectis Pharma, Inc. | $NVCT | Kaplan Matthew L. | Director | P | Common Stock | 11000 | $5.84 | 124,760.0000 | 22,719,057 | 9.67% | 0.05% |
| June 12, 2025 | Nuvectis Pharma, Inc. | $NVCT | Kaplan Matthew L. | Director | A | Common Stock | 30000 | $0.00 | 113,760.0000 | 19,937,507 | 35.82% | 0.15% |
| June 13, 2024 | Nuvectis Pharma, Inc. | $NVCT | Kaplan Matthew L. | Director | A | Common Stock | 30000 | $0.00 | 83,760.0000 | 16,559,335 | 55.80% | 0.18% |
| June 16, 2023 | Nuvectis Pharma, Inc. | $NVCT | Kaplan Matthew L. | Director | A | Common Stock | 18000 | $0.00 | 53,760.0000 | 14,724,249 | 50.34% | 0.12% |